嘉和生物-B(06998.HK)授出360.62万份受限制股份单位
格隆汇6月3日丨嘉和生物-B(06998.HK)发布公告,董事会已于2021年6月3日批准采纳2021年受限制股份单位计划。根据上市规则第17章,2021年受限制股份单位计划并不构成购股权计划,属公司酌情计划。采纳2021年受限制股份单位计划毋须取得股东批准。
根据2021年受限制股份单位计划,2021年6月3日,以零代价向51名参与者(为集团高级管理层及╱或雇员)授出3,606,249份受限制股份单位。参与者毋须就2021年受限制股份单位计划项下的任何受限制股份单位的授出或就所授出的受限制股份单位的归属支付任何款项。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.